NASDAQ: CDIOCardio Diagnostics Holdings Inc Stock
$0.23+0.01 (+4.55%)
Updated Oct 4, 2024
CDIO Price
$0.23
Fair Value Price
$0.00
Market Cap
$5.41M
52 Week Low
$0.17
52 Week High
$3.56
P/E
-0.54x
P/B
1.76x
P/S
317.7x
PEG
N/A
Dividend Yield
N/A
Revenue
$39.14k
Earnings
-$8.77M
Gross Margin
100%
Operating Margin
-20,682.64%
Profit Margin
-22,415.3%
Debt to Equity
0.3
Operating Cash Flow
-$5M
Beta
0.61
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CDIO Overview
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CDIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CDIO ($0.23) is overvalued by 80,492.29% relative to our estimate of its Fair Value price of $0.00 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CDIO ($0.23) is not significantly undervalued (80,492.29%) relative to our estimate of its Fair Value price of $0.00 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CDIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CDIO due diligence checks available for Premium users.
Be the first to know about important CDIO news, forecast changes, insider trades & much more!
CDIO News
Valuation
CDIO fair value
Fair Value of CDIO stock based on Discounted Cash Flow (DCF)
Price
$0.23
Fair Value
$0.00
Overvalued by
81,918.70%
CDIO ($0.23) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CDIO ($0.23) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CDIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CDIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.54x
Industry
-113.8x
Market
26.83x
CDIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.76x
Industry
5.96x
CDIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CDIO's financial health
Profit margin
Revenue
$7.9k
Net Income
-$1.3M
Profit Margin
-16,365.9%
CDIO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CDIO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$4.0M
Liabilities
$922.5k
Debt to equity
0.3
CDIO's short-term assets ($2.14M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CDIO's short-term assets ($2.14M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CDIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.2M
Investing
-$201.1k
Financing
$1.2M
CDIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CDIO vs Biotech Stocks
Cardio Diagnostics Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.